Skip to main content

Advertisement

Table 1 Clinical characteristics of patients

From: Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Variables Total (n = 701) 150 mg and 110 mg twice daily (n = 675) 75 mg twice daily (n = 26) P-value
Age, years 71.1 ± 10.9 70.8 ± 10.8 78.6 ± 10.0 0.004**
Gender, female (%) 244 (34.8%) 231 (34.2%) 13 (50.0%) 0.098*
Creatinine clearance: Ccr (mL/min) 68.7 ± 25.3 69.4 ± 25.3 53.5 ± 20.9 0.003*
History of bleeding 79 (11.3%) 74 (11.0%) 5 (19.2%) 0.191***
New users 354 (50.5%) 348 (51.6%) 6 (23.1%) 0.004***
Change from warfarin 232 (33.1%) 222 (32.9%) 10 (38.5%) 0.532***
C: Congestive heart failure 138 (19.7%) 128 (19.0%) 10 (38.5%) 0.002***
H: Hypertension 426 (60.8%) 406 (60.1%) 20 (76.9%) 0.041**
A: Aged 75 or older 294 (41.9%) 278 (41.2%) 16 (61.5%) 0.021**
D: Diabetes Mellitus 140 (20.0%) 133 (19.7%) 7 (26.9%) 0.117***
S: Stroke/TIA (2 points) 185 (26.4%) 177 (26.2%) 8 (30.8%) 0.327***
CHADS2 score 1.95 ± 1.35 1.92 ± 1.33 2.54 ± 1.77 0.011*
With antiplatelet agents 129 (18.4%) 125 (18.5%) 4 (15.4%) 0.686***
  1. Mean ± S.D., * t-test, ** Chi-square test, *** Fisher’s exact test